Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Instromedix' LifeSigns

This article was originally published in The Gray Sheet

Executive Summary

Instromedix' LifeSigns: Home-based patient monitoring system clears FDA, the Hillsboro, Oregon-based firm reports. The system is indicated for stabilized patients who may have compensated congestive heart failure, a history of myocardial infarction, symptoms of coronary artery disease, cardiac arrhythmias, conditions requiring Sp02 and high blood pressure monitoring and post-op cardiac recovery. Components of the system, which collects and transmits patient data to a medical facility via a standard telephone line, include the Shuttle, a portable patient monitor; the Commander, a telecommunications port for direct communication between patient and physician during data transfer; and the Central Station, a computerized patient management program...

You may also be interested in...



Pipeline Watch: Vericiguat, Evinacumab Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

EMA Set To Discuss Safety Of Ranitidine

Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.

Alvogen Aims To Be First On EU Pazopanib

Alvogen believes it is the first company to file for a generic pazopanib rival to Novartis’ Votrient oncology brand in Europe.

UsernamePublicRestriction

Register

MT009302

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel